Coronary Heart Disease
Conditions
Interventions
Treatment Group 1:Standard treatment plus Danlou Tablets (1.5g tid)
Treatment Group 2:Standard treatment plus Tongmai Yangxin Pills (4.0g bid)
Sponsors
Tianjin University of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
35 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Selecting people aged between 35 and 65; 2. Being up to the western diagnostic standard of chronic stable angina(complying with one or more of the following ): 1) There is a clear history of old myocardial infarction; 2) Have undergone coronary angiography or coronary Computed Tomography angiography(CTA) inspection hint antrum of coronary artery with at least a major branch pipe diameter stenosis>=50%; 3) Have received percutaneous coronary intervention (PCI) or Coronary Artery Bypass Grafting(CABG) treatment. 3. They should sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. Had history of myocardial infarction or unstable angina, or coronary artery revascularization in 3 months.(coronary artery bypass graft or angioplasty); 2. With other diseases that might cause chest pain, including heart diseases, neurosis, menopausal syndrome,hyperthyroidism, Cervical vertebra sickness (arteria vertebrals and spinal cord), gastroesophageal reflux disease or hiatal hernia; 3. Using three or more of these drugs,namely beta blockers, calcium channel blockers, Energy metabolism drugsand nitrate medications; 4. With hypertension and blood pressure after Anti-hypertensive Medical Therapy is still on the high side (systolic pressure =160 mmHg,diastolic pressure =100 mmHg)combined with severe cardiopulmonary insufficiency or severe arrhythmia (Rapid auricular fibrillation, atrial flutter or Paroxysmal Supra VentricularTachycardia); 5. Having liver disease or with unexplained serum transaminase continually increasing, or alanine aminotransferase(ALT) and aspartate aminotransferase (AST) greater than 2-fold of the upper limit of normal reference value; 6. Abnormal renal function; 7. Merger of hematopoietic system diseases, or a serious primary diseases such as malignant tumor; 8. Pregnant women, nursing mothers, or there is a requirement for fertility of women of childbearing age; 9. Diabetic kidney disease, severe gouty nephropathy and other metabolic diseases; 10. People with severe metabolic disease; 11. People who are expected with poor medical compliance or can't be visited on a regular basis; 12. Have participated in other clinical trials in recent 3 months; 13. Researchers considering there are other cases in which people are not suitable for attending the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Traditional Chinese Medicine symptom scores of Turbid Phlegm and Blood Stasis for Coronary Heart Disease; | — |
Secondary
| Measure | Time frame |
|---|---|
| The Short Form (36) Health Survey, (SF-36);Self-reporting Inventory(symptom checklist-90);ANG?;ANG II;ET-1;ApoA1;ApoB;ApoA1/ApoB;TC;TG;HDL-c;LDL-c;E-selection;P-selection;NF-?b;TNF-a;GMCSF;sSD40L;MCP-1;IL-1;IL-6;MMP2;MMP9;HCY;PT;TT;APTT;FIB;INR;Expression Profile Chip;Metabonomics;Seattle Angina Questionnaire;Proteomics; | — |
Countries
China
Contacts
Public ContactChunquan Yu
Outcome results
None listed